

iPDMO-Go

Integrated Personalised
Diabetes Management Goes Europe



FACT SHEET



iPDM-GO
Integrated Personalised
Diabetes Management
Goes Europe

Acronym

iPDM-GO

Full title

Integrated Personalised Diabetes Management Goes Europe

Programme


EIT Health

Contract number

19076

ABSTRACT

Our primary goal is to positively impact the lives of people living with type 2 diabetes by delivering integrated personalised diabetes management (iPDM). Through the development and delivery of personalised solutions and services, we strive to support diabetes self-management and improve citizens' quality of life. Furthermore, we believe that iPDM-GO can serve as a proof-of-concept for other chronic diseases, as we aim to realise outcomes-orientated healthcare in Europe. Integrated personalised diabetes management (iPDM) is a therapeutic approach that structures the diabetes treatment process, connects healthcare professionals and patients, and integrates digital tools that visualise and analyse data. iPDM is a process that supports healthcare professionals and their patients in their joint decision making. The iPDM concept consists of six steps (Figure).



The iPDM-GO consortium will implement iPDM in a Danish community setting with the goal of laying the groundwork for expanding to further European countries.

An international multi-stakeholder advisory board conduct a thorough health systems analysis and guide this scaling process. In parallel, the iPDM-GO consortium will develop a novel patient-assessment tool to enhance iPDM and personalise treatment to the specific needs and requirements of the individual person with diabetes.

The iPDM-GO tool will be co-created in a user-centric design process that considers early input from relevant stakeholders. Additionally, iPDM-GO will use machine learning methodologies to explore new opportunities for leveraging Big Data resources. We will also develop effective educational programs for healthcare professionals to learn about the key factors of success when implementing iPDM.

Importantly, to contribute to the transformation of healthcare from volume-based to value-based, iPDM-GO will develop a healthcare transformation toolkit that supports the implementation of value-based healthcare in European countries based on the iPDM process. With everyday life becoming increasingly digital, we aim to be at the forefront of the digital healthcare shift, bringing iPDM as a change-maker to the diabetes landscape. iPDM takes a modern digital approach to diabetes treatment that makes it easier for patients to communicate with their treating physicians.

Duration

36 months (01/01/2019 – 31/12/2021)

Project funding

2,736,962 EUR

Coordinator

Roche Diabetes Care Deutschland GmbH
Sandhofer Strasse 116
68305 Mannheim/Germany
email: allan.jones@roche.com

Partners

- University of Copenhagen
- Profil Institut für Stoffwechselforschung GmbH
- Capital Region of Denmark
- Deutsches Zentrum für Diabetesforschung e.V
- Danmarks Tekniske Universitet
- The City of Copenhagen
- The Region Sjælland

Project management

LINQ management GmbH
Julia Buech
Phone: +49 (0)30 300 96442
Email: j.buech@linq-management.com

Project website

www.eit-health.de/en/ipdm-go